Latest Period
Q4 2025
Security Snapshot
IOVANCE BIOTHERAPEUTICS, INC. - Common Stock (IOVA) Institutional Ownership
CUSIP: 462260100
13F Institutional Holders and Ownership History from Q2 2017 to Q1 2026
Institutions Reporting
259
Shares (Excl. Options)
261,537,672
Price
$2.73
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- IOVA on Nasdaq
- Shares outstanding
- 395,322,451
- Price per share
- $4.01
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 261,537,672
- Total reported value
- $713,890,828
- % of total 13F portfolios
- 0%
- Share change
- +48,394,739
- Value change
- +$134,068,635
- Number of holders
- 259
- Price from insider filings
- $4.01
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- IOVA - IOVANCE BIOTHERAPEUTICS, INC. - Common Stock is tracked under CUSIP 462260100.
- 259 institutions reported positions in Q4 2025.
- 3 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 259 to 113 between Q4 2025 and Q1 2026.
- Reported value moved from $713,890,828 to $177,954,845.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 259 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 462260100?
CUSIP 462260100 identifies IOVA - IOVANCE BIOTHERAPEUTICS, INC. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 462260100:
Significant Owners of IOVANCE BIOTHERAPEUTICS, INC. - Common Stock (IOVA) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 6.4% | $36,645,720 | 21,305,651 | BlackRock, Inc. | 30 Jun 2025 | |||
| STATE STREET CORP | 5.1% | $55,847,203 | 20,161,445 | STATE STREET CORPORATION | 31 Dec 2025 | |||
| PERCEPTIVE ADVISORS LLC | 3.8% | -50% | $45,599,285 | -$33,120,382 | 12,808,788 | -42% | Perceptive Advisors LLC | 31 Mar 2025 |
As of 31 Dec 2025, 259 institutional investors reported holding 261,537,672 shares of IOVANCE BIOTHERAPEUTICS, INC. - Common Stock (IOVA). This represents 66% of the company’s total 395,322,451 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of IOVANCE BIOTHERAPEUTICS, INC. - Common Stock (IOVA) together control 56% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 7.5% | 29,518,125 | +14% | 0% | $80,584,481 |
| MHR FUND MANAGEMENT LLC | 7.3% | 28,967,103 | 0% | 6.8% | $79,080,191 |
| VANGUARD GROUP INC | 6.9% | 27,207,079 | +13% | 0% | $74,275,326 |
| STATE STREET CORP | 5.1% | 20,161,445 | +51% | 0% | $55,040,745 |
| BANK OF AMERICA CORP /DE/ | 3.6% | 14,277,813 | +127% | 0% | $38,978,430 |
| Invenomic Capital Management LP | 3% | 11,959,505 | +13% | 1.6% | $32,649,449 |
| MORGAN STANLEY | 2.3% | 9,191,840 | +65% | 0% | $25,093,723 |
| GOLDMAN SACHS GROUP INC | 2.2% | 8,607,564 | +31% | 0% | $23,498,650 |
| Long Focus Capital Management, LLC | 2.2% | 8,600,000 | -5.7% | 1.2% | $23,478,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 7,991,640 | +16% | 0% | $21,820,558 |
| Palo Alto Investors LP | 1.8% | 7,116,676 | -6.6% | 2.7% | $19,428,525 |
| MILLENNIUM MANAGEMENT LLC | 1.7% | 6,585,532 | +49% | 0.01% | $17,978,502 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.3% | 4,948,614 | +50% | 0.02% | $13,509,716 |
| TWO SIGMA INVESTMENTS, LP | 1.1% | 4,397,989 | +60% | 0.02% | $12,006,510 |
| HRT FINANCIAL LP | 1.1% | 4,356,010 | +1078% | 0.04% | $11,891,000 |
| D. E. Shaw & Co., Inc. | 0.97% | 3,829,795 | +4925% | 0.01% | $10,455,340 |
| JANE STREET GROUP, LLC | 0.91% | 3,583,810 | +154% | 0.01% | $9,783,801 |
| CITADEL ADVISORS LLC | 0.8% | 3,143,091 | -18% | 0.01% | $8,580,638 |
| TWO SIGMA ADVISERS, LP | 0.76% | 3,015,000 | +185% | 0.02% | $8,230,950 |
| JPMORGAN CHASE & CO | 0.76% | 3,001,502 | +145% | 0% | $8,194,101 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.7% | 2,753,343 | +9.9% | 0% | $7,516,626 |
| NORTHERN TRUST CORP | 0.65% | 2,579,594 | +4.8% | 0% | $7,042,291 |
| WELLS FARGO & COMPANY/MN | 0.5% | 1,993,337 | +31% | 0% | $5,441,810 |
| Orion Investment Co | 0.47% | 1,856,934 | +0.28% | 1.6% | $5,069,430 |
| Rhenman & Partners Asset Management AB | 0.4% | 1,595,327 | +45% | 0.41% | $4,355,243 |
Institutional Holders of IOVANCE BIOTHERAPEUTICS, INC. - Common Stock (IOVA) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 50,723,573 | $177,954,845 | +$17,861,511 | $3.51 | 113 |
| 2025 Q4 | 261,537,672 | $713,890,828 | +$134,068,635 | $2.73 | 259 |
| 2025 Q3 | 213,023,331 | $462,262,436 | -$12,426,646 | $2.17 | 249 |
| 2025 Q2 | 220,039,758 | $378,480,610 | -$103,966,458 | $1.72 | 244 |
| 2025 Q1 | 239,455,648 | $797,796,916 | -$41,501,290 | $3.33 | 292 |
| 2024 Q4 | 241,507,506 | $1,786,983,312 | +$22,988,107 | $7.40 | 294 |
| 2024 Q3 | 235,201,336 | $2,210,596,727 | +$25,452,589 | $9.39 | 280 |
| 2024 Q2 | 232,474,427 | $1,864,558,933 | +$97,335,567 | $8.02 | 287 |
| 2024 Q1 | 217,101,064 | $3,216,301,753 | +$212,421,390 | $14.82 | 266 |
| 2023 Q4 | 207,297,037 | $1,685,397,432 | -$32,505,370 | $8.13 | 233 |
| 2023 Q3 | 213,137,480 | $969,776,344 | +$6,686,675 | $4.55 | 223 |
| 2023 Q2 | 203,959,385 | $1,435,734,710 | -$789,310 | $7.04 | 214 |
| 2023 Q1 | 205,425,383 | $1,254,751,936 | +$199,378,894 | $6.11 | 225 |
| 2022 Q4 | 173,249,347 | $1,106,975,435 | +$100,178,837 | $6.39 | 213 |
| 2022 Q3 | 154,414,415 | $1,478,691,442 | -$53,630,372 | $9.58 | 231 |
| 2022 Q2 | 156,417,705 | $1,726,071,008 | +$13,073,879 | $11.04 | 227 |
| 2022 Q1 | 155,843,237 | $2,593,671,140 | -$16,926,612 | $16.65 | 231 |
| 2021 Q4 | 155,850,778 | $2,963,320,040 | -$77,138,233 | $19.09 | 235 |
| 2021 Q3 | 157,966,360 | $3,882,977,675 | -$126,474,780 | $24.66 | 238 |
| 2021 Q2 | 162,111,422 | $4,215,394,735 | +$75,696,267 | $26.02 | 226 |
| 2021 Q1 | 156,513,608 | $4,954,837,773 | +$228,194,179 | $31.66 | 240 |
| 2020 Q4 | 148,752,147 | $6,902,468,525 | +$436,980,892 | $46.40 | 264 |
| 2020 Q3 | 139,955,271 | $4,606,819,956 | -$20,115,200 | $32.92 | 245 |
| 2020 Q2 | 140,811,545 | $3,876,458,222 | +$501,586,010 | $27.45 | 254 |
| 2020 Q1 | 122,545,305 | $3,667,866,974 | -$30,050,711 | $29.94 | 214 |
| 2019 Q4 | 124,152,367 | $3,436,416,158 | +$2,487,658 | $27.68 | 196 |
| 2019 Q3 | 123,451,560 | $2,246,787,056 | +$1,725,871 | $18.20 | 169 |
| 2019 Q2 | 122,286,530 | $2,995,401,566 | +$230,321,379 | $24.52 | 162 |
| 2019 Q1 | 117,236,707 | $1,114,459,029 | -$10,984,795 | $9.51 | 147 |
| 2018 Q4 | 118,553,949 | $1,048,865,157 | +$237,101,241 | $8.85 | 134 |
| 2018 Q3 | 90,396,956 | $1,016,473,349 | +$78,564,266 | $11.25 | 129 |
| 2018 Q2 | 83,236,651 | $1,065,503,232 | +$54,089,415 | $12.80 | 124 |
| 2018 Q1 | 77,770,935 | $1,312,527,807 | +$341,021,805 | $16.90 | 120 |
| 2017 Q4 | 57,639,452 | $460,738,120 | +$14,620,712 | $8.00 | 85 |
| 2017 Q3 | 55,295,141 | $428,707,093 | +$59,837,958 | $7.75 | 85 |
| 2017 Q2 | 47,622,569 | $349,319,767 | +$349,310,767 | $7.35 | 82 |